Suppr超能文献

局部应用多激酶抑制剂莫替沙尼(AMG 706)对小鼠实验性脉络膜新生血管形成的抗血管生成作用

Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.

作者信息

Rho Chang Rae, Kang Seungbum, Park Ki Cheol, Yang Keum-Jin, Choi Hyunsu, Cho Won-Kyung

机构信息

1 Department of Ophthalmology and Visual Science, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea , Daejeon, South Korea .

出版信息

J Ocul Pharmacol Ther. 2015 Feb;31(1):25-31. doi: 10.1089/jop.2014.0023.

Abstract

PURPOSE

To investigate the effect of topical motesanib, an inhibitor of receptor tyrosine kinase, on experimental choroidal neovascularization (CNV).

METHODS

CNV was induced in 46 nine-week-old male C57BL/6 mice using fundus laser photocoagulation. The right eye of each mouse was treated with motesanib eye drop (4 times daily) and the left eye with vehicle eye drop (4 times daily) for 14 days. To evaluate changes in the CNV lesions, fluorescein angiography, immunofluorescence staining with CD34, and histological examinations were performed 14 days after CNV induction. The expression of phosphorylated extracellular signal-regulated kinase (ERK1/2) in choroidal tissues was determined using western blot analysis to demonstrate the inhibitory effect of topically administered motesanib on intracellular signaling pathways involved in CNV development.

RESULTS

Fluorescein angiography showed that fluorescence leakage in eyes treated with topical motesanib was significantly less than in mice treated with vehicle (P=0.01). On immunofluorescence staining, the CD34-labeled area was smaller in topical motesanib-treated eyes (P<0.001). The expression level of phosphorylated ERK1/2 relative to that of total ERK1/2 decreased in eyes treated with topical motesanib compared with eyes treated with vehicle.

CONCLUSION

Topical motesanib significantly reduced laser-induced CNV in the experimental mouse model.

摘要

目的

研究受体酪氨酸激酶抑制剂莫特沙尼局部应用对实验性脉络膜新生血管(CNV)的影响。

方法

采用眼底激光光凝法在46只9周龄雄性C57BL/6小鼠中诱导CNV形成。每只小鼠的右眼用莫特沙尼滴眼液治疗(每日4次),左眼用赋形剂滴眼液治疗(每日4次),持续14天。在诱导CNV形成14天后,进行荧光素血管造影、CD34免疫荧光染色及组织学检查,以评估CNV病变的变化。采用蛋白质印迹分析测定脉络膜组织中磷酸化细胞外信号调节激酶(ERK1/2)的表达,以证明局部应用莫特沙尼对参与CNV形成的细胞内信号通路的抑制作用。

结果

荧光素血管造影显示,局部应用莫特沙尼治疗的眼睛荧光渗漏明显少于赋形剂治疗的小鼠(P = 0.01)。免疫荧光染色显示,局部应用莫特沙尼治疗的眼睛中CD34标记区域较小(P < 0.001)。与赋形剂治疗的眼睛相比,局部应用莫特沙尼治疗的眼睛中磷酸化ERK1/2相对于总ERK1/2的表达水平降低。

结论

在实验性小鼠模型中,局部应用莫特沙尼可显著减少激光诱导的CNV。

相似文献

本文引用的文献

5
Motesanib and advanced NSCLC: experiences and expectations.莫特塞尼布与晚期非小细胞肺癌:经验与展望。
Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. doi: 10.1517/13543784.2011.579103. Epub 2011 May 2.
8
Effect of sorafenib on experimental choroidal neovascularization in the rat.索拉非尼对大鼠实验性脉络膜新生血管的作用。
Clin Exp Ophthalmol. 2010 Oct;38(7):718-26. doi: 10.1111/j.1442-9071.2010.02328.x. Epub 2010 Jul 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验